FAM81B

Across TCGA pan-cancer cohorts, FAM81B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM81B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher FAM81B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM81B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, UCEC, and PRAD are the cancer types where FAM81B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.263	0.810	.015	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.029	12	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LIHC	DFS	Median	All	0.169	0.545	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM81B–KIRC (OS)

Open the KIRC breakdown →